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STEREOTACTIC RADIOSURGERY FOR INTRACRANIAL METASTASES 
FROM GASTROINTESTINAL MALIGNANCIES: A RETROSPECTIVE 
ANALYSIS 
MUHAMMAD FAZAL 
ABSTRACT 
Introduction: Cancers of the gastrointestinal tract are the second most prevalent malignancy with 
289,610 new cases last year and the second most common cause of cancer-related death with 
150,000 deaths last year in the United States. Prognosis for patients with these malignancies is 
poor and worsens significantly once the cancer has metastasized to the brain. We evaluated the 
outcome of patients following Stereotactic Radiosurgery (SRS) for brain metastases (BM) in 
individuals with GI cancers to identify safety and effectivity of treatment and we assessed 
prognostic factors that affect tumor control and survival. 
Objectives: By the conclusion of this session, participants should be able to: 1) Identify an 
effective treatment for brain metastases from GI cancers in terms of increasing survival; 2) 
Identify which treatment provides the best local and distant control of CNS disease; 3) Discuss 
the effects of different prognostic factors on local control and survival. 
Methods: This is a retrospective analysis of 58 brain metastases from 18 consecutive patients 
who underwent SRS treatment at BIDMC between 2006 and 2013. 11/18 patients underwent 
prior microsurgical resection for their metastases and 3/18 patients had undergone Whole Brain 
Radiation Therapy (WBRT). Overall Survival (OS), Local Control (LC), Distal control (DC), and 
prognostic factors such as age, number of brain metastases (BM), Karnofsky Performance Status 
(KPS), Recursive Partition Analysis (RPA) and Disease Specific Graded Prognostic Assessment 
(Ds-GPA) class were evaluated.  
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Results: The median overall survival (mOS) for the entire cohort was 14 months after the 
diagnosis of BM. The mOS for patients receiving only SRS, Surgical Resection + SRS, and 
WBXRT + SRS were 8 months, 18 months, and 13 months respectively.  The difference in 
overall survival between treatment groups was not found to be statistically significant. Increasing 
number of BM was a factor shown to negatively influence survival. Local control was achieved in 
55% of lesions after SRS, and in 75% of lesions that were surgically resected followed by SRS 
boost to the resection cavity. The difference in local control between SRS alone vs. Surgery + 
SRS was found to be statistically significant (p = 0.013). 
Conclusion: With a higher overall survival and significantly better local control rates, Surgery 
followed by SRS boost to the resection cavity should be considered as the treatment of choice in 
this specific subgroup of cancer patients as this study shows that they benefit from this more 
aggressive treatment option. 
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INTRODUCTION 
 
Cancers of the gastrointestinal (GI) tract represent the second most common 
malignancy in the United States with 289,610 estimated new cases in 2014 (Siegel, 
Miller, & Jemal, 2015). Despite advances in systemic therapy and treatment, GI tract 
cancers are also responsible for the second most common causes of cancer-related deaths 
and account for about 150,000 estimated deaths in the last year (Siegel et al., 2015). Out 
of these, cancers of the colon, rectum, and pancreas are most common and colorectal 
cancers (CRCA) are especially notorious for having a high mortality rate. It has been 
reported that about 50% of patients being afflicted by colorectal cancer will die of 
metastatic disease (Mongan et al., 2009). Malignancies of the colon and rectum represent 
the majority of cases from GI cancers. Due to the lack of studies done on all subgroups of 
GI cancers, or GI cancer patients as a whole, studies on colorectal cancer patients will be 
considered representative of GI cancers in this manuscript.  
For the purpose of this thesis, metastasis will be defined as the spread of cancer or 
disease from one part of the body to another that is not directly apposed or connected to 
the primary site (Klein, 2008). Brain metastases (BMs) are the most common form of 
intracranial tumors in adults and are about 10-fold times more abundant than primary 
brain tumors (Petrovich, Yu, Giannotta, O'Day, & Apuzzo, 2002). Most BMs are located 
at the gray-white matter junction, where there is a great reduction in the size of blood 
vessels which traps the metastatic emboli (Delattre, Krol, Thaler, & Posner, 1988). Brain 
metastases are a significant clinical problem as they occur in up to 40% of patients with 
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cancer of any histology depending on autopsy or radiological data (Hasegawa, 
Kondziolka, Flickinger, & Lunsford, 2003).  However, brain metastases from GI tract 
cancers are observed less frequently and are estimated to be present in 0.3 to 9% of 
patients only. On the other hand, 3 to 8% of all BMs are caused by GI cancers (Hasegawa 
et al., 2003). The occurrence of BMs is on the rise; this is in part due to better treatment 
options for the primary disease extending overall survival, but many of these therapeutics 
do not cross the blood-brain barrier. Another component of this increase is due to recent 
advances in imaging technology and diagnostics, enabling one to detect progressively 
smaller and clinically asymptomatic brain metastases (Hasegawa et al., 2003). Currently, 
patients with brain metastasis from any primary cancer have a poor prognosis, with recent 
studies typically indicating a median survival of less than 1 year (Zimmerman et al., 
2015).  Historically, median overall survival (OS) of patients with GI cancers metastatic 
to the brain was about 4 months which is much less than that of other leading cancers 
(Farnell et al., 1996). One reason is that brain metastases due to GI cancers present a 
troubling therapeutic problem due to their relative radio-resistance and their chemo-
resistant nature (Farnell et al., 1996). The particularly low rate of survival from GI cancer 
metastases to the brain may also be due to the differences in metastatic patterns between 
GI cancers and metastasis of other histologies. Brain metastasis is often the sole site of 
metastasis in lung cancer, whereas CRCA patients often (70 – 95%) have multiple 
regions of systemic metastasis when intracranial involvement is diagnosed (Fokas et al., 
2011). These most often include liver and lungs as tumor cells have to pass through both 
of these organ systems in order to reach the brain (Kye et al., 2012).  
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Even though overall survival rates of metastatic colorectal cancer have improved 
from far less than one year to about 24 months with improved systemic treatment, most 
of the therapeutics used in treatment regimens do not cross the blood-brain barrier, and 
hence do not control intracranial involvement (Grothey, Sargent, Goldberg, & Schmoll, 
2004). Currently, a number of CNS interventions are established, and include: whole 
brain radiation therapy (WBXRT), surgical resection, and stereotactic radiosurgery 
(SRS). These are most commonly used in conjunction with each other to treat brain 
metastasis, although no clear algorithm has emerged as the standard of care. However, 
most neurological oncology centers will attempt to proactively treat patients in good 
neurological condition and resect large, accessible, and symptomatic lesions before a 
patient undergoes either adjuvant SRS or WBXRT. On the other hand, Patients in poor 
neurological status or with rapidly progressing systemic disease have often be referred to 
palliative WBXRT only.  
Whole Brain Radiation Therapy (WBXRT) 
In the past 50 years, whole brain radiation therapy has been the standard treatment 
for patients with multiple BMs (Noura et al., 2012). Even today, this treatment option is 
still being frequently employed for the same reasons that made it a standard treatment of 
the past: It is a suitable and effective treatment option when there are multiple, bulky 
and/or inaccessible metastases; or too many metastases to allow for more focal treatment. 
It is also preferred when patients’ prognosis is poor and when the potential benefit from 
more resource intensive treatment is comparatively little. The most frequently used 
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algorithm of WBXRT consists of employing two parallel opposed beams (6 MeV photon 
fields) irradiating the entire brain using lead blocking devices for critical structures (Kaal 
& Vecht, 2006). The two most commonly applied WBXRT regimen are the delivery of 
either a total dose of 20 Gray (Gy) in 5 fractions or 30 Gy delivered in 10 fractions 
(amongst other schemes, depending on patient characteristics and tumor features). Many 
different fractionation schemes have been assessed but as of now, none have been shown 
to significantly improve overall survival times (Kaal, Niel, & Vecht, 2005). 
In 1990, Patchell and colleagues evaluated patients with a single metastasis to the 
brain. Their cohort consisted of a total of 48 patients, 25 of which received surgery 
followed by radiotherapy and 23 received radiotherapy alone. Patchell and colleagues 
showed that the median survival of patients receiving only WBXRT as the treatment for a 
single BM was 15 weeks (Patchell et al., 1990). Other studies comparing the use of 
WBXRT to no treatment have also shown similar median overall survival ranging from 
about 3-5 months (Petrovich et al., 2002). Subsequent trials and studies have tried to 
identify whether changing the dose or fractionation scheme improves survival, but these 
studies were unable to show a significant improvement in overall survival by using 
increased doses of WBXRT or hyper-fractionated therapy (Murray et al., 1997). 
In a patient population where quality of life in the foreseeable future is of 
importance, the treatment related toxicities from WBXRT become a concern. 
Furthermore, WBXRT comes with a time commitment that is burdensome, one that a 
large proportion of patients in this situation may not be able to bear. The 2-6 weeks that 
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WBXRT is also of great importance as it often requires halting of any other ongoing 
systemic therapy for that period of time.   
Short term toxicities associated with WBXRT, however not usually severe, 
include: fatigue, alopecia, reduced hearing, skin irritation, headaches, cerebral edema, 
and some general malaise. These problems interfere with the aim of increasing the quality 
of life in a patient with limited survival time. A RTOG randomized trial studied the 
effects of WBXRT on neurological function and investigated the concurrent deficits it 
causes (Sun et al., 2011). Neurological function was seen to have declined at 3 months 
from WBXRT although treatment associated deficits did not persist beyond the 6 month 
post treatment mark. However, a significant proportion of patients showed cognitive 
decline at both the 3 month and 1 year follow up assessment, as seen from the decline of 
early and delayed recall of information (Sun et al., 2011).  A more recent randomized 
study from 2009 by Chang and colleagues studied the cognitive effects of radiation 
treatment, and compared patients treated with SRS alone to patients treated with SRS + 
WBXRT. This study was terminated early because the authors had substantial evidence 
that the group undergoing SRS + WBXRT showed a significantly increased risk of 
neurocognitive decline at 4 months after treatment (E. L. Chang et al., 2009). However, it 
has been argued, that the negative consequences of an increased risk of recurrent CNS 
disease in the SRS only group (out of field observed tumor foci representing distal failure 
in patients treated by focal therapy alone) by far outweigh those complications caused by 
WBXRT – as experienced by the majority of patients.  
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Surgical Resection 
 A breakthrough in the management of brain metastases was a randomized trial by 
Patchell and colleagues (1990). This trial showed that for patients with a single brain 
metastasis, upfront surgical resection followed by radiotherapy greatly improved overall 
survival as well as greatly reduced the local recurrence rates while preserving or 
enhancing cognitive function. In this trial, patients in the surgery + radiotherapy group 
had a median overall survival of 40 weeks compared to OS of 15 weeks only for the 
group that received radiotherapy alone (Patchell et al., 1990). This was the first study that 
convincingly showed that aggressive management of brain metastases can help survival 
and neurological function. This study has since gained significant praise in the scientific 
community and is widely regarded as genuine evidence for the benefits of surgical 
intervention in patients with a single BM (Asher, Burri, & Shaffrey, 2005). However, one 
must bear in mind that only 30% of all cancer patients with BM are suitable candidates 
for open microsurgical intervention (Sheehan, Kondziolka, & Ryken, 2006).  
 Even though surgery is considered the standard treatment in patients with a single 
resectable BM and good prognostic factors, some studies argue that it should also be 
considered in patients with multiple BMs (Kaal & Vecht, 2006). Since there are no 
prospective randomized trials on this subject, the best available evidence comes from a 
retrospective study of 56 patients (Bindal, Sawaya, Leavens, & Lee, 1993). In this study, 
patients were divided into two groups: group 1 contained patients who had undergone 
unsuccessful resection of up to three BMs; group 2 contained patients who had 
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undergone successful resection of up to three BM. Patients from the second group were 
then matched with a third group that had patients identical to the second group, but who 
had only a single BM which was resected (Bindal et al., 1993). The authors reported a 
median OS of 6 months for patients in group 1 and 14 months for patients in group 2 and 
3. This led them to the conclusion that careful surgical resection of multiple BM in 
selected patients can improve  the OS, as does resection in patients with single BM 
(Bindal et al., 1993).  
 Hence, surgery has been shown to clearly improve OS in patients with a single 
BM but it should also be considered in selected patients with multiple BM. That being 
said, the added risks of surgical morbidity from resecting multiple metastases or those 
metastases in locations which are difficult to access must be kept in mind when 
considering such surgical interventions (Asher et al., 2005). 
Stereotactic Radiosurgery (SRS) 
 Devised by Swedish neurosurgeon Lars Leksell, stereotactic neurosurgery or 
stereotactic radiosurgery (SRS) is a method of delivering radiation to a target zone with a 
dose that ablates any target tissue (e.g. tumor) and is therefore considered as effective as 
surgical removal (Chan, Cardinale, & Loeffler, 2004). Using magnetic resonance imaging 
(MRI), computed topography (CT), and in many cases angiography, SRS systems 
precisely define target coordinates in the head or body of a patient who is immobilized 
for targeting.  Such a radiation delivery system is in full synchrony with a target 
localization system thus allowing the precise delivery of a pre-defined radiation dose to 
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the target volume identified in its specific location. Due to these features, this  method 
allows focused radiation delivery to e.g. tumor tissue and at the same time significantly 
reduces any radiation  dose to the surrounding non-affected brain parenchyma (Chan et 
al., 2004). Whereas surgical intervention allows for  an instantaneous removal of any 
accessible intracranial lesion, SRS offers a non-invasive way of tissue destruction as 
means of treatment for small, inaccessible intracranial tumors and other target lesions 
(Hong, Fogarty, & Izard, 2012). 
Currently there are several commercial SRS systems available: 
a) Cobalt-60 based Leksell GammaKnife (GK) SRS. 
Having been in the field for over 40 years, the GammaKnife SRS unit uses 201 
60Cobalt sources positioned on a half-hemisphere or “shell” as a point source. The 
technical arrangement allows collimation of the emitted radiation into a beam, 
with each beam aimed at the center of the targeting system, creating a spherical 
volume or irradiated target tissues called a single isocenter. Using various 
collimators in the metal helmet, homogeneity across the beam and at the isocenter 
can be achieved.  Any patient undergoing treatment is then positioned in such a 
way that the isocenter “overlays” the lesion, creating a spatial match of the target 
structure to the radiated volume, - and the congruence of those two volumes is 
expressed in a measure called “conformity index”. If the lesion is large or 
irregularly shaped, more than one treatment sessions using different isocenters 
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with overlapping spheres is usually employed (Lim, Hsu, Rigamonti, & 
Kleinberg, 2013). 
The most striking feature of the GammaKnife unit is the precise imaging to 
control isocenter location. This is due to the fact that during treatment, both the 
GK unit and the patient are absolutely immobilized via a fixed frame which is 
physically attached to the patients head and also to the radiation unit. The 
immobility allows for treatment with multiple isocenters in a short amount of 
time. The newest version of the GK (Perfection) incorporates an automatic 
positioning system (APS) that automatically  adjusts the head frame coordinates 
and positions the patient and couch to align the target at each isocenter (Brown & 
Pollock, 2005). The GammaKnife SRS system is most commonly used for small 
brain tumors (< 35mm) and functional brain disorders (Lim et al., 2013). 
 
b) Proton beam SRS 
Protons are charged particles that can be accelerated to move in straight 
trajectories to form a “pencil beam” of radiation which then can deliver discrete 
amounts of kinetic energy into target tissue at which the beam is aimed at. This 
makes proton beam delivery systems an appealing choice for the irradiation of 
intracranial pathologies. Furthermore, because of very sharp lateral edges, the 
radiation dose displays a fall off to nearly zero to the side. Due to the particle 
nature of the radiation beam, the penetration depth is related to the kinetic energy 
of the protons and will stop  with practically no exit dose just deep to the target 
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structure (Lim et al., 2013). This makes proton beam SRS a very attractive choice 
for large and/or irregular tumors or those adjacent to critical structures where 
sparing of unaffected brain parenchyma is essential (Chan et al., 2004). 
The planning stage in this system can take up to weeks as customized collimators 
have to be manufactured for each patient. The need for large capital investment to 
build a facility to produce the proton beam (generally through a cyclotron) is the 
reason that these systems are not widely available (Miller, 1995) 
 
c) Linear-Accelerator (LINAC) based SRS 
LINAC-based SRS systems started off in the 1980s and have now become the 
most widely used SRS systems in modern clinical centers. This is another method 
of generating and delivering focused radiation to diseases of the CNS. The 
radiation beam is generated by a LINAC emitting photons and these beams are 
shaped and administered through multiple arcs which allow highly conformal 
dosing due to overlapping spherical isocenters. Even though the LINAC-based 
SRS technique is more suited towards treating regular sized pathologies with 
contours that can easily be matched with spherical isocenters, though methods for 
treating odd or irregular shapes have also been devised recently. By either using 
multiple arcs or dynamic radiosurgery, which uses a single arc but rotates the 
treatment couch and the gantry, overlapping isocenters can be achieved. This 
coordinated movement of the couch and gantry allows for delivery of maximum 
radiation to the target while largely sparing healthy tissue (Lim et al., 2013).  
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Some LINAC systems allow for fractionated treatment during multiple sessions, 
which is something difficult to achieve through other devices with fixed frames.  
More recently developed SRS systems can also be used to treat extra-cranial 
pathologies as long as the available imaging technique guarantees precise 
localization of the target. Since most LINAC– based technique involve moving 
equipment parts or the patient, it has been argued that the precision of radiation 
delivery is less than that of the GK, which is stationary and employs a fixed frame 
(Asher et al., 2005). Another disadvantage of photon based systems is that the 
dose fall off is exponential with increasing depth causing an increase of radiation 
delivery to non-affected tissue (Lim et al., 2013). 
CyberKnife (CK) SRS 
Developed at Stanford University and available since the late 1990s, the 
CyberKnife is a robotic, frameless, real-time image guided SRS system. It brings together 
the features of a LINAC assembly with that of an industrial robot (J. R. Adler, Jr., 
Murphy, Chang, & Hancock, 1999). The four main components of the CK are the 
LINAC, x-ray imaging system, robot, and a stereo camera system (J. R. Adler, 2005). It 
uses a LINAC emitting 6 MeV photon beams and can deliver radiation up to a rate of 4 
Gy/min (Lim et al., 2013). With three rotational, and three translational axes, the CK 
comes with a total of six degrees of movement (Hara, Soltys, & Gibbs, 2007). Since it 
has such high maneuverability, this allows delivery of the radiation beams to the target 
from any angle, making it possible  to generate treatment plans that are non-isocentric 
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(Nangiana, Adler, & Chang, 2011). A position of the robot in 3D-space is assumed for 
treatment and is considered a point source called a “node”. The CK robot can 
theoretically use up an infinite number of such positions during treatment, but 
traditionally 100- 300 nodes per treatment are being used which generates a very uniform 
distribution of the dose. These features make the CyberKnife the most flexible of all SRS 
systems currently available (Brown & Pollock, 2005). 
Another feature of the CK is that there is no need for a rigid head frame fixed to 
the patient’s skull for the treatment. Instead, a semi-flexible, non-invasive, individually 
formed “Aquaplast-mask” is used and fixed to the treatment couch to eliminate head 
movements (S. D. Chang, Main, Martin, Gibbs, & Heilbrun, 2003). Furthermore, 
throughout the treatment session, x-ray images of the treatment target area are taken 
repeatedly and these real-time coordinates are compared stored digitized images of the 
intended coordinates from the simulation session to ensure high accuracy of the radiation 
plan during delivery. This elegant tracking system can account for any patient movement 
and if detected, the robotic arm and LINAC are brought to a new position before the 
treatment resumes (Brown & Pollock, 2005; Nangiana et al., 2011). Unlike conventional 
LINAC systems that claim accuracy in millimeters, the CK-system allows for sub-
millimeter accuracy in tumor tracking and dose delivery (Kurup, 2010).  
Some of the shortcomings of the CK system are its prolonged treatment sessions 
lasting from 30 to 60 minutes per target volume, as well as its inability to maintain high 
uniformity in dosing when used to treat larger target volumes (Kurup, 2010).  
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SRS is generally well tolerated by patients and its side-effects are comparatively 
little, infrequent and if they do occur, they are usually self-limiting. Acute side-effects are 
commonly due to cerebral edema and include headaches and nausea. These can usually 
be relieved by the use of corticosteroids to control the edema (Brown & Pollock, 2005). 
Radiation necrosis is by far the most serious side-effect of any SRS treatment, occurring 
in less than 5% of cases (Hong et al., 2012). Radiation necrosis is the destruction of brain 
parenchyma which may either be limited in size or appears to be growing over time 
(Asher et al., 2005). If the resulting edema from necrosis cannot be controlled by 
corticosteroids, addition of Bevacicumab (Avastin®) or surgical intervention may be 
required (Hong et al., 2012). 
The first large cohort multi-center study into the effectiveness of SRS in the 
treatment of brain metastases and comparison with WBXRT was a retrospective analysis 
performed by Sanghavi et al in 2001. The study included 502 patients from 10 different 
clinical centers and aimed to examine whether addition of SRS to WBXRT leads to a 
survival benefit as did the addition of surgery to WBXRT (Sanghavi et al., 2001). This 
study showed patients receiving WBXRT + SRS had a significantly improved median OS 
of 16.1, 10.3, and 8.7 months for patients stratified according to RPA classes 1, 2 and 3 
respectively when compared to the median OS of patients undergoing WBXRT alone 
(which was 7.1, 4.2, and 2.3 months for RPA class 1, 2 , and 3 respectively). In 2004, the 
largest study to date comparing the efficacy of WBXRT +SRS to WBXRT alone was 
conducted by Andrews et al. In this study, the median OS of patients with only 1 BM (of 
any given primary tumor) was 4.9 months in the group that had received WBXRT alone. 
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When supplemented with SRS, it was shown that the median OS increased by 1.6 months 
to an avarage of 6.5 months (Andrews et al., 2004). Even though such a survival benefit 
was not seen in patients harboring 2-3 BM, it was noted that these patients had a much 
higher performance status at 3 and 6 months post treatment when a SRS boost was added 
to the WBXRT (Andrews et al., 2004). Some authors have even tried to extend the use of 
SRS to patients with 10 or more BM (Grandhi et al., 2012; Jawahar et al., 2005). In the 
study by Grandhi and colleagues (2012), it was found that in about 80% of their patients, 
stable lesions with comparable local control rates (LCRs) were achieved. This led them to 
conclude that SRS can also be effectively used to treat patients with 10 or more BMs. 
 Having been presented with the data proving the efficacy of surgery as well as 
SRS in the treatment of brain metastases, one can see why a lot of studies have been 
conducted to evaluate whether WBXRT has to be administered at all (E. L. Chang et al., 
2009; Jensen et al., 2011; Sneed et al., 1999). One particular prospective trial that 
included 95 patients with a single BM evaluated the benefit of adding WBXRT to 
complete resection of such tumors (Patchell et al., 1998). All 95 patients received 
successful surgery before randomization to either receiving WBXRT or no further 
treatment. Patchell and colleagues (1998) reported that there was no significant difference 
in overall survival and there was no difference in the time interval that patients remained 
functionally independent in the two groups. However, patients in the group that received 
WBXRT had significantly less local (10% vs. 46%) and distant (14% vs. 37%) tumor 
recurrence and were much less likely to die of neurological cause (14% vs. 44%).  
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A separate prospective randomized trial studied the use of SRS compared to SRS 
+ WBXRT in patients exhibiting 1-3 new BMs (E. L. Chang et al., 2009). This study 
included 58 patients who either received SRS alone or SRS + WBXRT. The authors 
concluded that even though the SRS only group showed significantly better 
neurocognitive function several months after treatment, this group also had a higher 
tumor recurrence rate. This study also showed an improved median survival in the group 
that received SRS alone, but attributed that to the fact that 33% of those patients had to 
undergo surgical resection for pathological identification of the active tumor site. To sum 
up, the role of WBXRT, in conjunction with surgery or SRS, remains a controversial 
topic with the need for further well designed studies (Hong et al., 2012; Sneed et al., 
2002).  
Prognostic Indices and the DS-GPA   
With the advancement of therapeutic options allowing to simultaneously treat 
systemic as well as intracranial progression of cancer, studies have tried to identify 
prognostic factors to better understand and possibly prolong the patient’s overall survival 
without any unnecessary interventions (Eichler & Loeffler, 2007). To this end the 
Radiation Therapy Oncology Group (RTOG) conducted multicenter clinical trials which 
enrolled a large number of patients and the survival results after WBXRT for these 
patients have been analyzed (Gaspar et al., 1997; Sperduto et al., 2012) . Based on the 
database of 1200 patients from the RTOG trials, recursive partition analysis (RPA) was 
performed to identify clinically meaningful prognostic groups. The result was the 
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formation of three distinct groups into which patients were placed based on age, 
performance score (KPS), and extent of disease and/or progression. The prognosis of 
patients in different groups varied significantly with this stratification and hence the RPA 
classification became a standard tool in studies on prognostication in patients with brain 
metastases. The RPA groups and their descriptions are shown in Table 1.  
 
Table 1: Recursive Partition Analysis (RPA) classification and median survival. (Taken 
from data presented by Gaspar et al., 1997.)  
RPA Class Classification Criteria Median Survival after 
WBXRT 
Class I Age < 65, KPS ≥ 70, 
controlled primary 
disease, and only brain 
metastases. 
7.3 months 
Class II All other patients 4.2 months 
Class III KPS < 70 2.3 months 
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Table 2: Karnofsky Performance Status Scale Definitions Criteria. Taken from (Schag, 
Heinrich, & Ganz, 1984) 
 
Able to carry on normal 
activity and to work; no 
special care needed. 
100 Normal no complaints; no evidence of 
disease 
90 Able to carry on normal activity; minor signs 
or symptoms of disease. 
80 Normal activity with effort; some signs or 
symptoms of disease. 
 
Unable to work; able to 
live at home and care for 
most personal needs; 
varying amount of 
assistance needed. 
70 Cares for self; unable to carry on normal 
activity or to do active work. 
60 Requires occasional assistance, but is able to 
care for most of his personal needs. 
50 Requires considerable assistance and 
frequent medical care. 
 
 
Unable to care for self; 
requires equivalent of 
institutional or hospital 
care; disease may be 
progressing rapidly. 
40 Disabled; requires special care and 
assistance. 
30 Severely disabled; hospital admission is 
indicated although death not imminent. 
20 Very sick; hospital admission necessary; 
active supportive treatment necessary. 
10 Moribund; fatal processes progressing 
rapidly. 
0 Dead 
 
The weaknesses of the RTOG RPA stratification became apparent after it failed to 
produce any prognostic effect in some retrospective studies (Nieder, Andratschke, Grosu, 
& Molls, 2003). One of these weaknesses includes the lack of a diagnosis-specific 
distinction, which questions the validity of the data. Since the trials upon which the RPA 
classifications are based were done before the turn of the century, it is commonly 
believed that they do not adequately represent the advancements made in systemic 
therapy (Sperduto et al., 2012).  For these reasons Sperduto and colleagues developed a 
newer prognostic index, for patients with brain metastases, which was published in 2010 
(Sperduto et al., 2010). This so called "Graded Prognostic Assessment" (GPA) was 
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developed from four RTOG trials that included a total of 1960 patients. The GPA took 
into account the number of BM present in patients but originally did not include the 
histopathology of the primary tumor in its analysis either. The GPA was then further 
refined to include the histopathology of the primary tumor and this was  achieved through 
a retrospective analysis of 3940 patients with BM, ultimately resulting in the Disease-
specific Graded Prognostic Assessment (Ds-GPA) (Sperduto et al., 2012). The GPA is 
scored out of 4.0 and a patient with a GPA of 4.0 has the best prognosis. For people with 
GI cancers, a GI specific GPA has been created by Sperduto and colleagues (2012). They 
found that the only statistically significant prognostic factor for OS in GI cancers is the 
KPS. This is in contrast to other kinds of cancers such as lung cancer, melanoma, and 
renal cell carcinoma, where age, number of BM, and KPS were found to be prognostic. 
The GI specific GPA is shown below.  
 
Table 3: GI-specific GPA. Taken from (Sperduto et al., 2012). 
 GPA Scoring Criteria 
Prognostic Factor 0 1 2 3 4 
KPS <70 70 80 90 100 
 
Specific Aims and Objectives of our Study 
Even though WBXRT was considered a good treatment option, recent 
randomized trials have reported disappointing outcomes for WBXRT alone in the 
treatment of brain metastases (Andrews et al., 2004; Fogarty et al., 2011). In general, 
most studies recommend a combination of surgery and WBXRT or surgery and SRS 
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(Suzuki et al., 2014). Recently, SRS has been emerging as the first choice treatment for 
many patients with both large and  small brain metastasis and it has been shown to be 
effective in the treatment of brain metastasis regardless of the primary histology 
(Schoeggl, Kitz, Reddy, & Zauner, 2002). Some authors have even suggested that SRS is 
as effective, if not better, than surgery in treating BM with excellent local tumor control 
and acceptable toxicity levels in patients (Schoeggl et al., 2002). 
This study reviews the institutional experience of the Beth Israel Deaconess 
Medical Center (BIDMC) in Boston, Massachusetts with a LINAC-based SRS system 
(CyberKnife) over a study period from 2005 to 2013 for the treatment of patients with 
BM from histologically defined GI cancers.  
The primary objective of this study is to measure OS, LCR, and Progression Free 
Survival (PFS) for these patients based on the treatment or combined modalities that they 
underwent. Secondly, we aim to identify prognostic factors that suggest a better or worse 
outcome for patients in regards to resulting survival and local control rates. These results 
will then be discussed against the current research background available in literature to 
provide significant information to assess the efficacy of one treatment modality over 
others in treating patients with BM from GI cancers. 
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METHODS 
Study Design 
 This study was performed as a retrospective analysis of a prospectively collected 
data base on patients that have undergone SRS for brain metastasis from primary GI 
cancers between 2005 and 2013. Data were taken from BIDMC’s longitudinal database 
containing all radiation oncology and radiosurgery patients. Patient characteristics were 
obtained via a comprehensive review of their complete medical records. This included 
patient demographics (age, gender), primary disease information (histology, anatomy, 
disease status at the time of SRS, location and number of BM treated, performance status, 
systemic disease status at the time of treatment and in follow up and all documented 
clinical presentations), and patient history (medications, risk factors, family history, 
administered treatment, response to treatment, as well as date of death and/or last follow 
up). The technical data-set regarding treatment details for each patient were obtained 
from a second longitudinal database maintained by the CK (Multiplan Software) at the 
BIDMC Keith Fields CK Center. This data-set included SRS specific treatment 
characteristics (such as tumor volume, tumor location, number of beams and units 
employed, and percentage of volume coverage, isodose lines, and homogeneity index), 
surgical characteristics, as well as WBXRT characteristics (dose and fractionation 
scheme). Imaging reports for each individually treated lesion were carefully reviewed 
pre-treatment, during treatment, as well as at predetermined intervals (1, 3, 6, 12, and 24 
months) after treatment. Follow up imaging studies were obtained in form of a contrast 
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enhanced MRI and this data set was reviewed by a board-certified neuro-radiologist 
whose report was taken into consideration when assessing tumor response. In cases 
where no autopsy information was available, all hospital and cancer center records 
including the complete patient medical records, imaging studies and all office evaluations 
for progression of disease were reviewed in order to derive at an informed decision 
regarding the cause of death.  Exact dates of death were either obtained through these or 
other registries at BIDMC as well as all publicly available death registries.  
Patient Population 
 Patients with brain metastasis from primary GI cancer who were treated with 
CyberKnife SRS (Accuray, Sunnyvale, CA, USA) at the Departments of Radiation 
Oncology and Neurosurgery at BIDMC between 2006 and 2013 were identified for this 
study. A total of 57 lesions from 18 such patients from BIDMC’s database were obtained. 
A minimum of 12 months had to elapse after the treatment session to allow an end point 
event to occur and to be included in this study.  
Seventeen of the patients were dead by the time of analysis and one patient is still 
alive. All patients underwent complete primary and systemic work-up before treatment 
with SRS. Patient performance status was assessed and registered using the Karnofsky 
Performance Scale. Lastly, all patients were classified according to the following 
prognostic indices: Recursion Partition Analysis (RPA) classes according to RTOG, and 
Diagnosis-specific Graded Prognostic Assessment (Ds-GPA). Both these methods were 
used to allow a prognostic stratification of patients included in this study. 
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The CyberKnife Treatment at BIDMC 
 The CyberKnife Robotic Radiosurgical System has been available at the BIDMC 
since 2005 (see Figure 1). All patients that underwent SRS for the treatment of BM in 
this cohort were treated with this system. Before the decision to deliver radiation therapy 
is made, a complete evaluation of all patient cases, scans, and reports is undertaken in a 
weekly interdisciplinary tumor conference at the Brain Tumor Center (BTC). This 
conference includes a team of neurosurgeons, neurologists, neuro-oncologists, neuro-
radiologists, radiation oncologists, and neuro-pathologists who discuss each case and 
make sure all aspects are being considered before a treatment recommendation is made. 
The patient, who is to undergo SRS, would then be asked to come in the same week for 
treatment planning.  
This simulation and planning appointment would include generation and testing 
immobilization using an Aquaplast mask (WFR/Aquaplast Corp., Wyckoff, NJ) which is 
most frequently applied in the supine position. As described earlier, this mask serves as 
an external immobilization device that does not need rigid skeletal fixation point. Upon 
construction of a custom mask for the patient, a treatment planning and simulation 
session in the final treatment position is undertaken.  
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Figure 1: The Keith Fields CyberKnife Center at BIDMC in Boston, MA 
 
During this planning session, a high resolution, contrast enhanced (via 
administration of Iohexol [Omnipaque; G.E. Healthcare Inc., Princeton, NJ]) CT with a 
1.25-mm slice thickness is obtained using a General Electric Light Speed 8i or 16i 
scanner (Milwuakee, WI). These CT scans are fused with MRI that the patient 
subsequently receive in order to enhance target identification. All imaging studies are 
then entered into Accuray’s Multiplan software (See Figures 2 and 3). 
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Figure 2: This representative anonymized screen shot image is taken from the BIDMC 
database and shows a typical treatment plan for a patient with intracranial metastases. 
This image of the MultiPlan software displays the sagittal, axial, and coronal scans of a 
patients head with the target volumes delineated.  
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Figure 3: This screen shot of another anonymized image taken from the BIDMC database 
illustrates the graphic user interface of Accuray’s MultiPlan software. On the left is a 
visual representation of the various angles with which irradiation beams can target the 
tumor volume (top panel) and on the bottom is an axial CT scan with superimposed 
isodose lines of the intended radiation plan; on the right, a histogram representing the 
dose-volume relationship is shown as well as a dose statistics table.  
 
 The team of a dedicated radiation oncologist and the respective neurosurgeon then 
review the computer-generated dose distributions (isodose lines) and determine whether 
they are accurate or need to be modified. After a satisfactory plan has been generated, it 
is loaded onto a recording system and verified by the Mosaiq Radiation Oncology 
Information System (Elekta Instruments AB, Stockholm, Sweden). An average treatment 
session takes up to 45 minutes per target volume with this system. The eligibility of each 
patient was determined before they were signed up to undergo SRS treatment. All 
patients that underwent SRS were adults (age > 18 years), had histologically confirmed 
diagnosis of GI cancer through a biopsy of the metastasis or from the primary site, and 
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had a maximum tumor diameter limited to 3 cm. Further eligibility criteria required that 
no severe neurological deficit due to mass effect or edema was present and that the 
resulting KPS was above 70.  
Follow-up 
 Patients were followed from the diagnosis of their disease and the moment of 
indication to perform SRS treatment until the time of death. Follow up was scheduled as 
early as 1 month post SRS with a new MRI scans and clinical follow-up examination. 
From there, follow-up imaging and examination was conducted every 2-3 months upon 
the discretion of the multidisciplinary team at the BTC. When MRI imaging was 
contraindicated (e.g. in the setting of a cardiac pacemaker), CT scans were performed and 
used to assess the tumor site. Three patients (17%) died within a month from the date of 
SRS treatment from unforeseen non-neurological causes and hence were censored from 
further local and distant control analyses but still included in the description of the cohort 
and were also represented in the overall survival analyses.  
Outcome Measures 
 The outcome measures of this study were overall survival (OS), local control rate 
(LCR), distant control rate (DCR), local and distant progression free survival (PFS). OS 
was calculated as the time from the date of diagnosis of brain metastasis to the date of 
death. Local control was defined as: no further tumor growth after treatment and no 
evidence of post-SRS complications (such as symptomatic hemorrhage or radiation 
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necrosis in follow up scans necessitating surgical intervention) (Selek et al., 2004). Local 
control was further divided into Complete Response (CR), Partial Response (PR), and 
Stable Disease (SD). Any lesion not following the above criteria was defined as a local 
failure and lesions were called Non-Responders (NR). In cases where surgical resection 
preceded SRS, local control was defined as the absence of any new nodular enhancement 
adjacent to the resection cavity on follow up scans. Distant Control was defined as the 
absence of any new intracranial lesions (other than at the site of treatment) on follow up 
scans. Local and Distant progression free survival (PFS) was calculated as the time from 
the date of SRS to the date of appearance of local or distant failure respectively. The 
cause of death of all patients was assessed and sorted into two groups, depending whether 
it was neurological or non-neurological. If patients displayed stable systemic disease but 
progressive intracranial disease at the time of last follow up, a neurological cause of 
death was assumed. Whereas, if intracranial disease was controlled but systemic disease 
was progressive (infection, organ failure, or hemorrhage), a non-neurological cause of 
death was assumed (Do et al., 2009). For patients receiving WBXRT as salvage therapy, 
control rates were censored at the time of WBXRT. Otherwise, patients were censored at 
the time of last follow up scan.  
Statistical analysis  
 For all the variables under study, frequencies and descriptive statistics were 
analyzed. Kaplan-Meier analyses were conducted in order to calculate OS, Local and 
Distant Control, as well as PFS. Post-treatment time intervals were assessed in months 
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from the date of treatment. In terms of prognostic indices, univariate as well as 
multivariate analyses were performed using the Cox proportional hazards model. The 
log-rank test was used for univariate analyses in the comparison of categorical variables. 
In all the analyses, a value of 0.05 was used to define statistical significance. The 
standard statistical software SPSS 20 (IBM) and the freely available Power and Sample 
Size calculator 3.1.2 (Vanderbilt, USA) were the only statistical software used for the 
purposes of this thesis.  
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RESULTS 
Patient Characteristics 
The entire cohort consisted of 18 patients harboring a total of 58 distinct brain 
metastases. There were 12 male (67%) and 6 female (33%) patients. Age of patients 
ranged from 37 to 79 years with a median age of 57 years at the time of presentation. The 
median KPS at initial presentation was 80; 7 patients (39%) had KPS ≤ 70, and 11 
patients (61%) had a KPS > 70. Only 5 patients (28%) had a single BM, 8 patients (44%) 
had between 2 and 4 BM, and 5 patients (28%) had more than 4 BM. The median number 
of BM per patient was 1.50 (range: 1-10). Location of the primary malignancy was the 
colon in 9 patients (50%), the rectum in 4 patients (22%), and the esophagus in 5 patients 
(28%). Before SRS treatment was first undertaken, a comprehensive systemic disease 
survey was conducted in all patients (Torso CT, PET and brain imaging via MRI). Four 
patients (22%) had metastatic disease in the brain only, compared to 14 patients (78%) 
who presented with synchronous extra-cranial metastasis along with intra-cranial ones. 
Classification of patients according to the most commonly used prognostic classes, as 
described earlier, was performed. According to the Recursive Partition Analysis (RPA) 
classification established by the RTOG, 4 patients (22%) were classified as RPA class I, 
13 patients (72%) as RPA class II, and 1 patient (6%) as RPA class III. Stratification 
according to the Disease-Specific Graded Prognostic Assessment (Ds-GPA) resulted in 3 
patients (17%) being classified as Ds-GPA 4, 5 patients (28%) as Ds-GPA 3, 3 patients 
(17%) as Ds-GPA 2, 6 patients (33%) as Ds-GPA 1, and 1 patient (6%) as Ds-GPA 0.  
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Treatment Characteristics 
Cyberknife Stereotactic Radiosurgery was performed independent of any ongoing 
or planned treatment regimen aimed at treating the systemic disease. All patients received 
peri-interventional prophylactic corticosteroids (dexamethasone, Decadron ®) as well as 
anti-seizure medication (levitiracetam, Keppra ®) after SRS treatment. Four patients 
(22%) received SRS only, 11 patients (61%) received upfront microsurgical resection of 
their tumor followed by SRS boost to the resection cavity, and 3 patients (17%) received 
WBXRT before being treated with SRS, as boost or as salvage therapy. SRS treatment 
characteristics are provided in the table below.  
Table 4: Treatment Characteristics of SRS 
Variable N (%) 
No. of patients 18 
No. of lesions 54 
Stereotactic Radiosurgery  
Median tumor volume (cm3) 0.63 
Range of tumor volume (cm3) 0.075-77.13 
Median no. of beams 219 
Median monitor units 14732 
Median dose (Gy) 22 
Median no. of fractions 1 
Median coverage (%) 96.22 
Median isodose line (%) 77 
Median conformity index 1.24 
Median homogeneity index 1.25 
Median min. dose (Gy) 19.70 
Median max. dose (Gy) 27.40 
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Study Results 
Overall survival 
As stated earlier, at the time of analysis, 17 patients (94%) had died and only 1 
patient (6%) was alive. Of the patients who had died, 2 patients (12%) died due to 
progression of intracranial disease (neurological death), 8 patients (47%) died due to 
systemic disease progression (non-neurological death), and the cause of death for 7 
patients (41%) could not be determined. The median overall survival (mOS) for the entire 
cohort was 14 months (95% CI 7.07-20.93 months) after the diagnosis of BM. The 
actuarial OS rates for the entire patient cohort were 94.4% (n=17) at 1 month, 83.3% 
(n=15) at 6 months, 66.7% (n=12) at 12 months, and 22.2% (n=4) at 24 months after the 
diagnosis of BM. The median OS for patients with a single BM was 18 months (95% CI 
12.16-23.84 months) compared with only 5 months for patients with multiple BM (n > 4) 
(p = 0.006). Median overall survival was significantly different between RPA class I and 
III. Patients in RPA class I had a mOS of 19 months (95% CI 0-48.52), compared to mOS 
of 5 months for patients in RPA class III (p = 0.046). When stratifying the patient cohort 
by treatment modality, patients who received only SRS did the worst in terms of overall 
survival with mOS of 8 months (95% CI 0-20.74). Patients who received Surgery 
followed by SRS boost to the resection cavity did the best with mOS of 18 months (95% 
CI 10.45-25.55) and patients who received WBXRT before treatment with SRS had mOS 
of 13 months (95% CI 0.2-25.8). The effect of treatment modality on overall survival was 
not found to be statistically different (P = 0.611). The Kaplan-Meier plots of overall 
survival stratified by different modalities are shown. 
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Figure 4: Kaplan-Meier plot showing overall survival for the entire patient cohort.  
This plot was generated using SPSS 20.0 software package. 
 
 
Figure 5: Kaplan-Meier plot showing overall survival for patients with KPS ≤ 70  
and those with KPS > 70. This plot was generated using SPSS 20.0 software  
package. 
 
P = 0.614 
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Figure 6: Kaplan Meier plot showing overall survival of patients that received  
surgery and patients who did not. The plot was generated using SPSS 20.0  
software package. 
 
 
Figure 7: Kaplan-Meier plot showing overall survival between patients who had  
Only brain metastases at the time of presentation vs. patients who had systemic 
metastases.This plot was generated using SPSS 20.0 software package. 
P = 0.181 
P = 0.205 
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Figure 8: Kaplan-Meier plot of overall survival comparing patients that presented  
with a single BM vs. those that presented with multiple (n > 4) BM.  
This plot was generated using SPSS 20.0 software package. 
 
Patients who only had brain metastasis at the time of their initial presentation had 
a longer median overall survival (19 months - 95% CI 0-42.52) when compared to mOS 
of 13 months (95% CI 10.5-15.5) for patients who also had systemic metastases. 
However, this difference was not found to be statistically significant (p = 0.21) (Figure 
7). When comparing three different treatment groups (SRS only, surgery + SRS, 
WBXRT + SRS), the difference in overall survival was not found to be significant. 
However, actuarial 1-year OS rates were 50% for patients who received SRS alone, 
72.7% for patients receiving Surgery + SRS, and 66.7% for patients receiving WBXRT + 
SRS. Below are Kaplan-Meier plots comparing single vs. multiple brain metastasis, 
different treatment modalities, and the survival of patients when stratified by RPA and 
Ds-GPA classification.  
P = 0.006 
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Figure 9: Kaplan Meier plot of overall survival comparing the different treatment 
modalities (SRS alone vs. Surgery + SRS vs. WBXRT + SRS).  
This plot was generated using SPSS 20.0 software package. 
 
Figure 10: Kaplan-Meier plot of overall survival for three patient groups stratified 
by RPA class. This plot was generated using SPSS 20.0 software package. 
P = 0.611 
P = 0.095 
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Figure 11: Kaplan-Meier plot of overall survival for five patient groups stratified 
by Ds-GPA classification. This plot was generated using SPSS 20.0 software  
package. 
 
In univariate analysis, there were trends to increased survival in patients with KPS 
greater than 70, for patients with prior surgical resection of a brain metastasis, for patients 
with no extracranial metastases, for patients with single BM, for patients categorized as 
RPA class I as well as Ds-GPA class 4. However, of all these factors, only RPA class and 
Ds-GPA class remained statistically significant as prognosticators (P = 0.05 and P = 0.03 
respectively). It must be noted that when KPS and number of BM were used as 
continuous variables, rather than dichotomous, statistically significant prognostication 
appeared. An increase in KPS by 1 unit led to a decrease of 6% in the chances of hazard 
(death) (P = 0.05). An increase of 1 unit in the number of brain metastases led to a 50% 
increase in the chances of death (P = 0.03). However, since dichotomous variables 
P = 0.22 
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provide better clinical prognostication, and comparison to previously conducted studies, 
we decided to include only dichotomous variables in our table of results.  
In multivariate Cox analysis, age, KPS, presence of extracranial metastases, 
number of BM, and treatment modality were tested. Due to the low number of patients in 
our cohort, and the relatively rarity of GI cancer metastasizing to the brain, it was 
difficult to prove statistical significance. However, clear trends to increased survival were 
seen with KPS > 70, absence of any extracranial metastases, for cases presenting with a 
single BM, and for patients being treated with surgery or WBXRT before SRS treatment. 
The results of univariate and multivariate analyses are shown in Table 5. 
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Table 5: Univariate and Multivariate analysis of prognostic factors affecting  
Overall survival. This was generated using SPSS 20.0 software package. 
(HR = Hazard Ratio) 
  ------Univariate-------- --------Multivariate--------  
Variable # HR 95% CI P 
value 
HR 95% CI P 
value 
mOS 
Age      <65 14 1.00   1.00   18 
             ≥65 4 1.14 0.32-4.09 0.84 0.476 0.08-2.87 0.42 5 
KPS         
≤70 7 1.00   1.00   9 
>70 11 0.77 0.27-2.20 0.62 0.35 0.08-1.50 0.16 18 
Surgery         
No 7 1.00      13 
Yes 11 0.51 0.18-1.42 0.20    18 
Other mets         
Brain only 4 1.00   1.00   19 
Extracranial 14 2.23 0.61-8.11 0.22 3.28 0.72-14.99 0.13 13 
Primary Histology         
Esophageal 5 1.00      13 
Colon/Rectum 13 0.85 0.29-0.46 0.76    18 
Number of BM         
Single 9 1.00   1.00   18 
Multiple 9 1.52 0.57-4.09 0.41 2.01 0.59-6.89 0.27 12 
Treatment Type         
SRS 4 1.00   1.00   8 
Surgery + SRS 11 0.43 0.12-1.49 0.18 0.34 0.08-1.36 0.13 18 
WBXRT + SRS 3 0.69 0.15-3.29 0.65 0.32 0.05-2.06 0.23 13 
RPA Class         
1 4 1.00      19 
2 13 2.13 0.58-7.83 0.25    14 
3 1 15.14 1.07-215 0.05    5 
Ds-GPA         
0 1 1.00      5 
1 6 0.11 0.01-1.38 0.09    9 
2 3 0.15 0.01-1.99 0.15    18 
3 5 0.17 0.01-2.07 0.17    13 
4 3 0.04 0.00-0.71 0.03    29 
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Tumor Control 
 
 For the purpose of local and distal control analysis, patients who were not seen at 
last follow up but did not have any neurological symptoms following treatment and died 
a non-neurological death (according to the definition provided in the ‘Outcome 
Measures’ section) were assumed to have maintained local and distant control of their 
CNS disease. The three patients mentioned initially, who died within 1 month of 
treatment, were excluded from tumor control analyses. A total of 15 patients with 52 
intracranial lesions made up the cohort used in our local and distant tumor control 
analysis. Over the course of the entire follow-up period, local control was achieved in 
61.5% (n = 32) of the lesions regardless of treatment modality. Of the 40 lesions that 
were treated with SRS alone, 22 lesions (55%) were locally controlled over the course of 
the study. Eight lesions were microsurgically resected before employing SRS treatment to 
the resection cavity - leading to a local control rate of 75%. This difference between SRS 
alone and Surgery + SRS was found to be statistically significant (P = 0.013). Since only 
4 lesions from 1 patient were treated with WBXRT, leading to local control of all four 
lesions, the treatment modality of WBXRT is excluded from the local control analyses.  
In this study, the 1-year LCR for lesions that were treated with SRS alone was 38.2% 
whereas the lesions that were microsurgically resected before treatment with SRS to the 
resection cavity had a 1-year LCR of 85.7%. The Kaplan-Meier plot displaying local 
tumor control stratified according to treatment modality is shown in Figure 12. 
 40 
 
Figure 12: Kaplan-Meier plot showing local tumor control stratified by treatment 
type. This plot was generated using SPSS 20.0 software package. 
 
 The median Local Progression Free Survival (LPFS) for the entire cohort was 14 
months from the date of SRS treatment. The differences between treatment groups in 
terms of LPFS were not significant. In univariate analyses, a colorectal primary histology 
led to a 60% increase in the hazard ratio for local failure, whereas Surgery + SRS, 
multiple fractions, higher conformity index, and higher homogeneity index were 
associated with favorable local tumor control. On multivariate Cox analysis, Surgery + 
SRS, as well as a higher conformity index showed obvious trends towards favorable local 
tumor control however statistical significance could not be achieved. The univariate and 
multivariate results from the Cox proportional hazards model are displayed in Table 6.  
 
 
 
 
P = 0.013 
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Table 6: Univariate and Multivariate analysis of local tumor control. Performed using 
SPSS 20.0 software package. (HR = Hazard Ratio) 
  ---------Univariate---------- ---------Multivariate----------- 
Variable # HR 95% CI P value HR 95% CI P value 
Primary Histology        
Esophageal 18 1.00      
Colon/Rectum 34 1.60 0.53-4.84 0.40    
        
Treatment Type        
SRS 40 1.00   1.00   
Surgery + SRS 8 0.30 0.07-1.29 0.11 0.47 0.05-3.25 0.44 
        
Target Volume        
<=3cm3 35 1.00   1.00   
>3cm3 12 0.79 0.28-2.21 0.65 2.22 0.42-11.83 0.35 
        
Fractions        
Single 42 1.00   1.00   
Multiple 3 0.65 .09-4.89 0.68 0.18 0.01-5.0 0.32 
        
Dose  1.07 0.84-1.36 0.58 1.34 0.83-2.36 0.21 
        
Conformity Index  0.37 0.02-6.54 0.49 0.50 0.03-9.1 0.64 
        
Isodose Line  1.08 0.95-1.22 0.24 1.12 0.98-1.28 0.10 
        
Homogeneity Index  0.009 0-35.86 0.26    
 
 Distal failure was defined as the appearance of a metastatic focus at any site in the 
brain other than the site of prior radiation treatment. Distal failure was observed 32 
lesions (61.5%) over the entire follow up period. The overall median Distant Progression 
Free Survival (DPFS) was found to be 6 months from the date of SRS treatment. For 
lesions treated with SRS alone, a median of 6 months elapsed before occurrence of 
distant failure, for Surgery + SRS the median DPFS was found to be 10 months, and for 
WBXRT + SRS the DPFS was 9 months. Differences in DPFS between treatment 
modalities were not found to be statistically significant. The Kaplan-Meier plot 
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displaying the proportion of patients with distant control against the time from SRS 
treatment is shown in Figure 13.  
 
Figure 13: Distant Control in patients stratified by three different treatment groups. 
This plot was generated using SPSS 20.0 software package.  
 
 In univariate analysis of Distant Control, trends with better distant control were 
seen with colorectal primary histology, absence of extracranial metastases at the time of 
presentation, and Surgery + SRS treatment. However, only the absence of extracranial 
metastases at the time of presentation remained statistically significant (P = 0.02). These 
factors were also used in multivariate Cox analysis. Having a colorectal primary 
histology was associated with increased distant control (HR: 0.5, P = 0.12). Treatment 
with Surgery + SRS, and WBXRT + SRS were seen to positively affect distant control 
with hazard ratios of 0.43 and 0.31 (P = 0.09) respectively. The only independent and 
statistically significant factor negatively affecting distant control of tumor was the 
presence of extracranial metastases at the time of presentation (HR: 13.7, P = 0.01).   
P = 0.349 
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DISCUSSION 
The primary objective of this retrospective study was to identify a suitable and 
effective treatment option for this specific subgroup of cancer patients who have a 
gastrointestinal tract malignancy which has metastasized to the brain. As stated earlier, 
prognosis for this group of patients is rather poor, with median survival times ranging 
from two to ten months (Alden, Gianino, & Saclarides, 1996; Mege et al., 2013). In this 
study, we found the median overall survival time after the time of diagnosis of BM to be 
14 months. This is higher than commonly reported mOS, most likely due to the large 
proportion of patients undergoing surgical resection of their BM before adjuvant SRS or 
WBXRT in this cohort. It has been reported that the overall mOS of patients with GI 
cancer metastasized to the brain is shorter than that of most other primary cancers 
(Hasegawa et al., 2003). This can be, in part, attributed to the apparent radioresistant and 
chemoresistant nature of these metastases (Farnell et al., 1996). In our study, patients 
who underwent microsurgical resection of their metastases had a much higher median 
overall survival (18 months) than patients that underwent either prior WBXRT or SRS 
only (13 months and 8 months respectively). However, with a cohort of 18 patients, it 
was not possible to demonstrate statistical significance.  
In univariate analysis, a KPS > 70, microsurgical resection, absence of 
extracranial metastases, single BM, RPA class 1, and Ds-GPA class 4 were associated 
with increased survival. When tested in multivariate analysis we adjusted for confounders 
that may interfere with analyzing the effect of different treatment on survival outcome. 
KPS > 70, absence of extracranial metastases, and surgery + SRS treatment were 
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associated with much lower hazard ratios. However, none of these prognostic indices 
were statistically significant for the sample size analyzed here.  
Two of the patients in our study, who underwent upfront microsurgical resection 
followed by SRS boost to the resection cavity, lived more than 5 years from the time of 
diagnosis of BM. One of these patients is still alive and has not had any CNS-recurrence 
of cancer. It has to be noted that these patients presented with good performance status 
and no active systemic disease, which does bias them towards increased survival. They 
were hence placed in favorable RPA and Ds-GPA classes. Similar results were seen by 
Farnell and colleagues (1996) who identified factors that resulted in long-term survivors 
from patients with CRCA and brain metastasis. Most of the long-term survivors 
identified in their study had undergone upfront microsurgical resection followed by 
radiotherapy in the form of fractionated WBXRT (Farnell et al., 1996).  
In terms of survival, our results correlate well with existing studies on CRCA or 
GI cancers as a whole. Most studies on CRCA or GI cancers are retrospective in nature 
and hence no conclusive statement about the optimal treatment algorithm can be made. 
However, Wronski and colleagues (1999) followed the work of Patchell and colleagues 
(1990) and showed that surgical resection of BMs from CRCA lead to an increase in 
survival times (Wronski & Arbit, 1999). Their patient cohort consisted of patients who 
had a maximum of three BMs from CRCA, presented with limited extracranial disease, 
and had an estimated life expectancy of over 6 months. Wronski and Arbit showed that in 
this cohort of patients, median overall survival after surgery was 8.3 months with two 
long standing (> 5 years) survivors (Wronski & Arbit, 1999). This median overall 
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survival of 8.3 months was a noticeable increase from the median survival of patients 
with BMs from CRCA reported in another study from the same period. In the latter study, 
the patients were treated with WBXRT only and had a median survival of 2.8 months 
only (Alden et al., 1996). While a number of studies have shown a clear survival benefit 
associated with SRS treatment, such a benefit was not obvious in our study.  A review of 
the existing literature on GI cancers or CRCA (representing the bulk of GI cancers) is 
presented in Table 7. 
  
  Table 7: Review of existing studies on CRCA and GI cancers. (*Rtx = SRS or WBXRT).  
Series Year # 
patients 
Primary 
Histology 
Treatment 
modality(s) 
Median OS Indication 
Current 
Study 
2015 18 Gastro-
intestinal 
1) Surgery + SRS 
2) SRS alone 
3) WBXRT + SRS 
1) 18 months 
2) 8 months 
3) 13 months 
Overall – 14 months 
Surgery + 
SRS/WBXRT as the 
treatment of choice for 
GI brain metastases. 
Suzuki et al. 2014 113 Colorectal 1) Surgery + WBXRT 
2) SRS alone 
3) WBXRT alone 
1) 10.5 months 
2) 5.1 months 
3) 3.1 months 
Overall – 5.4 months 
Surgery + WBXRT as 
the treatment of choice 
for CRCA brain 
metastases. 
Mege et al. 2013 28 Colorectal 1) Surgery 
2) Surgery + WBXRT 
Overall – 12 months Surgery with or 
without WBXRT. 
Noura et al. 2012 29 Colorectal 1) Surgery only  
2) Surgery + Rtx* 
3) SRS only 
4) WBXRT only 
1) 5.1  months 
2) 11.4 months 
3) 7 months 
4) 7.9 months 
Overall – 7.4 months 
Surgery + WBXRT 
Kye et al. 2011 39 Colorectal 1) Surgery 
2) WBXRT 
3) SRS 
1) 15.2 months 
2) 4.4 months 
3) 6 months 
Overall – 5 months 
Surgical resection of 
CRCA brain 
metastases. 
Jung et al. 2011 126 Colorectal 1) Surgery + WBXRT 
2) SRS only 
3) WBXRT only 
1) 11.5 months 
2) 9.5 months 
3) 4 months 
Overall – 5.4 months 
Surgery +/- SRS for 
CRCA brain 
metastases. 
Fokas et al. 2011 78 Colorectal 1) Surgery + WBXRT 
2) SRS only 
3) WBXRT only 
1) 14 months 
2) 7 months 
2) 9 months 
Overall – 8 months 
Surgery +/- Rtx  
4
6 
  
 
 
 
 
 
 
 
Series Year # 
patients 
Primary 
Histology 
Treatment 
modality(s) 
Median OS Indication 
Hasegawa et al. 2003 39 GI 1) WBXRT + SRS 
2) Surgery + SRS 
1) 5 months 
2) 11 months 
Overall – 9 months 
Surgery for large 
accessible lesions. 
SRS for deep 
lesions 
Schoeggl et al. 2002 35 Colorectal 1) SRS only 
2) SRS + WBXRT 
Overall – 6 months SRS  
Petrovich et al. 2002 13 Colorectal SRS 6 months  
Ko et al. 1999 53 Colorectal 1) Surgery 
2) WBXRT 
1) 86.6 months 
2) 2.9 months 
Surgery 
Farnell et al. 1996 150 Colorectal 1) Surgery + WBXRT 
2) WBXRT alone 
1) 9.8 months 
2) 4 months 
Overall – 4.8 months 
Surgery + 
WBXRT as the 
treatment of 
choice. 
Alden et al.  1996 19 Colorectal WBXRT 2.8 months  
4
7
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As can be seen from Table 7, SRS alone leads to a median overall survival time 
ranging from 5-9.5 months whereas incorporating surgical resection into the treatment 
regimen increases the median overall survival to well over a year. This, along with our 
current study may be seen as a valid argument that, whenever possible, surgery should be 
included in the treatment regimen for brain metastases from GI tract cancers. The 
efficacy of WBXRT could not be properly assessed in our study due to the small number 
of patients in that treatment group. 
 In the assessment of local tumor control, most studies on metastatic CRCA and GI 
cancers to the brain report overall local control rates ranging from 80% to 96% using 
SRS (Fokas et al., 2011; Hasegawa et al., 2003; Schoeggl et al., 2002).  In the current 
study, the observed local control rate in the group undergoing SRS treatment only was 
much lower than those rates reported by the other researchers. We achieved a local 
control rate of 55% in the tumors treated by SRS. In comparison, the tumors that were 
microsurgically resected before being given SRS boost had a local control rate of 75%. 
Part of this difference may be explained by selection bias if patients with better 
performance status (e.g KPS > 90) were included in the previous studies.  However, the 
notable finding is that the difference in local control rates between the two groups (SRS 
alone vs. surgery + SRS) were found to be statistically significant (P = 0.013). We 
believe the low LCR achieved by employing SRS alone could be, in part, due to the 
presence of soft tissue extensions (microinfiltrations surrounding the visible lesions)  that 
stem from the more invasive nature of these GI-metastases themselves. When applying 
SRS to these lesions, radiation teams frequently plan a clinical target volume that is 
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slightly larger than the size of the tumor. However, we have to consider that by being 
"conservative" and providing a tight dosimetric plan with high conformity (trying to harm 
as little peri-focal parenchyma as possible) the SRS alone treatment is missing these 
micro-extensions of metastases from which the tumor then might recur.  
 This observation is further reinforced by the univariate analysis on factors 
affecting local tumor control. The conformity index is a measure of how well the 
prescription isodose planned by the SRS device fits the target volume of the CNS disease. 
Conformity index is calculated using the formula:𝐶𝐼 = 𝑉𝑅𝐼/𝑇𝑉, where VRI is the 
prescription isodose volume and TV is the target volume. As shown in Table 6, according 
to this study, an increase in 1 unit of the conformity index reduces the chances of local 
failure by 50%, however this result was not found to be statistically significant. 
Nevertheless, this finding points towards a possible cause for the high number of local 
failures in the group undergoing SRS alone and a possible adjustment that could be 
looked into in order to improve the local control for brain metastases from GI cancers 
that are being treated with SRS alone.  
 In distant control analyses, no statistically significant difference was seen in the 
different treatment groups of SRS only vs. surgery + SRS. Only the absence of 
extracranial metastases at the time of presentation was significantly associated with better 
survival (P = 0.01). This is because the absence of extracranial metastases indicates to a 
large extent that systemic disease status was stable or controlled which would disallow 
further seeding of metastases to the brain.  
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Before the discovery of the so called FOLFOX treatment regimen for colon and 
GI cancers, the median survival for patients with metastatic colon cancer was less than a 
year. Nowadays, the mOS of metastatic CRCA has been raised to about 21-24 months 
(Kye et al., 2012). However, when the cancer has metastasized to the brain, FOLFOX 
regimen does not help with intracranial control as these medications do not cross the 
blood-brain barrier. With the advancement of radiation therapy techniques, the 
introduction of SRS, and increases in safety of surgery, intracranial disease can be 
controlled to a much better extent. Hence, as seen in this study, only 2 patients died from 
solely neurological causes (progression of brain disease), while most of the patients died 
from systemic progression of disease. To effectively extend the lifespan and quality of 
life for individuals with metastatic GI cancer to the brain, a multidisciplinary approach 
must be employed where the systemic disease has to be controlled so that further 
metastatic seeding to the brain cannot take place. This concept is essential, especially in 
cases in which SRS is employed as the only radiation treatment modality for the CNS 
since this therapy is target focused and does not help control the entirety of the 
intracranial compartment. The distant control rate in our patient cohort was rather low at 
38.5% regardless of type of treatment, which reflects the need to better control systemic 
disease alongside modern intracranial treatment methods. 
Limitations of the study: 
 The limitations of the study include its retrospective nature, limited number of 
patients, and a possible treatment selection bias inherent in such studies. Neurosurgeons 
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are ethically required to resect lesions in patients who presented with large, symptomatic, 
and accessible lesions to relieve the symptoms. Our sizeable yet small patient cohort was 
hence not perfectly homogenous and follow up imaging was not available for some 
patients who needed to be censored from the study. Since only a few patients received a 
single treatment modality, it was difficult to assess the selective impact of individual 
treatment options on this type of neoplastic CNS disease. Lastly, due to the fact that some 
of our patients had multiple metastases and some had only single metastases (and the fact 
that the progression or control of metastases may well depend on the aggressiveness of 
the individual tumor type), improper weightage may have been introduced by patients 
with multiple metastases when analyzing local and distant control rates. 
Future Research Agenda: 
 Due to the small size of the cohort, additional findings in this study could still be 
statistically significant. For that very reason, the trends that were noticed in this study 
(such as the increased effectiveness of surgery + SRS compared to SRS alone in local 
control of tumor, the association of extracranial metastases with distant failure, and 
association of higher conformity index with better local control) must be further 
evaluated in a prospective setting or in a large multi-center retrospective study. We 
calculated the sample size that would be required to achieve a power of 80% with a 
significance of < 0.05 in order to conclusively evaluate the difference between surgery + 
SRS vs. SRS alone in terms of local tumor control as well as overall survival. The 
minimum number of patients required in such a study was calculated to be 84, using the 
 52 
PS Power and Sample Size Programs free software. Due to the improper weightage of 
some patients, we also plan on using Frailty models which would account for this 
problem. Since this is a feasible number and will provide us with significantly more 
statistical power to draw meaningful conclusions, we shall attempt to establish a 
multicenter collaboration in the near future to accrue this number of patients for further 
analysis.  
Conclusion: 
 The primary objective of this study was to identify an effective treatment 
modality to treat brain metastases from GI cancers. We believe that surgery followed by 
radiation therapy (SRS) represents the best course of action for brain metastases from GI 
cancers. With a significantly improved local control rate and higher overall survival, 
surgery followed by a SRS boost to the resection cavity should be considered the 
treatment of choice for this subgroup of patients as this study shows that these patients 
did benefit from this aggressive treatment algorithm. With regards to the use of SRS to 
treat multiple brain metastases, we believe that due to the histology of these metastases 
and their projections, SRS alone is not effective enough in controlling the disease or 
extending lifespan with the currently employed regimen. Steps need to be taken and 
studies conducted in order to evaluate a new dose regimen or increased conformity and 
treatment volumes (with added treatment margins to extend the prescription isodose) in 
order to properly irradiate likely existing microscopic extensions from which the tumors 
would otherwise recur.   
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